US Patent

US8513249 — Methods and compositions for safe and effective treatment of erythema

Method of Use · Assigned to Galderma Laboratories LP · Expires 2031-03-25 · 5y remaining

Vulnerability score 73/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods and compositions for treating erythema or a symptom associated with erythema using a topical brimonidine composition.

USPTO Abstract

Improved methods and compositions for safe and effective treatment of erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.4% to about 0.6% by weight of brimonidine and a pharmaceutically acceptable carrier.

Drugs covered by this patent

Alphagan (BRIMONIDINE TARTRATE) · Senju Pharmaceutical Co., Ltd

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1428`	—	Alphagan

Patent Metadata

Patent number: US8513249
Jurisdiction: US
Classification: Method of Use
Expires: 2031-03-25
Drug substance claim: No
Drug product claim: Yes
Assignee: Galderma Laboratories LP
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.